RecruitingPhase 2NCT03304821

Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease

Studying Isolated femoral agenesis/hypoplasia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Emory University
Principal Investigator
Arshed Quyyumi, MD
Emory University
Intervention
GM-CSF(drug)
Enrollment
176 target
Eligibility
21-85 years · All sexes
Timeline
20172025

Study locations (1)

Collaborators

National Heart, Lung, and Blood Institute (NHLBI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03304821 on ClinicalTrials.gov

Other trials for Isolated femoral agenesis/hypoplasia

Additional recruiting or active studies for the same condition.

See all trials for Isolated femoral agenesis/hypoplasia

← Back to all trials